Clinical trial · no report yet · Phase 3
Celestimo
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
- NCT04712097 ↗
- Active not recruiting
- Hoffmann-La Roche
- 26 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 17 | |
| Podcasts | 6 | |
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a Non-Randomized Single Arm US Extension of Mosunetuzumab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Relapsed or Refractory Follicular Lymphoma
- Interventions
- Mosunetuzumab; Lenalidomide; Rituximab; Tociluzumab
- Arms
- M + Len (Arm A) · Experimental
- R + Len (Arm B) · Experimental
- M + Len (US Extension Arm C) · Experimental
- Enrollment
- 478
- Primary outcomes
- Progression Free Survival (PFS) according to 2014 Lugano Response Criteria
- Sponsor
- Hoffmann-La Roche
- Start
- Oct 27, 2021
- Primary completion
- Jun 3, 2026
- Results posted
- No
- Registry record
- NCT04712097 · updated Oct 8, 2026